Seattle, WA, United States
Seattle, WA, United States

Time filter

Source Type

Patent
VentiRx Pharmaceuticals | Date: 2016-10-11

The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2017-04-26

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.


Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer and infectious diseases, named Michael J. Kamdar, Chief Executive Officer and Director at Molecular Assemblies Inc., and Todd N. Smith, Chief Executive Officer at Novum Pharma, to the company’s Board of Directors. “Mike and Todd add depth, experience and leadership to an already distinguished group of leaders on the Vault Pharma Board of Directors,” said Mr. Oliver Foellmer, President & CEO at Vault Pharma. “With Mike and Todd, Vault Pharma is in a stronger position to transition into and be successful in the commercial stages of our product development.” Vault Pharma is developing a unique therapeutics platform using the body’s own naturally occurring vault protein particles found abundantly in human cells to activate the immune system against cancer cells, bacteria and viruses. The vault particle was discovered by Vault Pharma Founder Dr. Leonard Rome, a Professor at the David Geffen School of Medicine at UCLA. As CEO at Molecular Assemblies, Mr. Kamdar leads the company that is developing a proprietary enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. Mr. Kamdar has accounted for deal transactions in excess of $1 billion and has raised more than $400 million from venture capital and public capital markets. Previously, Mr. Kamdar was President and Founder of VentiRx Pharmaceuticals, an immuno-oncology company focused on TLR8 agonists acquired by Celgene. Mr. Kamdar currently serves on the board of directors at Prime Genomics, Medipacs (Chairman) and Cellana. Mr. Smith has more than 20 years of pharmaceutical, medical device and biotechnology leadership experience. He has a reputation for building companies and leading them to commercial success and business development excellence. Mr. Smith has led high-performing commercial teams at Bayer, Abbott, Horizon Pharma, Agouron Pharmaceuticals and Fenwal, Inc. Mr. Smith currently is CEO at Novum Pharma, a global specialty pharmaceuticals company focused on providing innovative therapeutic solutions and ensuring treatment access for patients. Vault Pharma is expected to introduce its lead drug candidate, VPI-101, into Phase I clinical trials in 2017. A potential cancer immunotherapy treatment, VPI-101 has shown effectiveness in lung cancer, glioblastoma (brain tumors) and melanoma. VPI-101 successfully completed preclinical animal efficacy and active ingredient phase I safety trials. Vault Pharma, with headquarters in Los Angeles, Calif., is a leading immunology-focused biotechnology company developing and commercializing immunotherapy treatments for cancer and infectious diseases. Vault Pharma’s mission is to develop safe and effective immunotherapeutics that will transform existing treatment paradigms.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2015-11-04

The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some embodiments, preferred methods according to the disclosure also allow for the preparation of benzazepine derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. The methods disclosed herein find utility in synthetic organic chemistry as well as medicinal chemistry.


Patent
Array BioPharma and VentiRx Pharmaceuticals | Date: 2013-09-03

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.


Patent
Array BioPharma and VentiRx Pharmaceuticals | Date: 2012-01-12

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.


Patent
Array BioPharma and VentiRx Pharmaceuticals | Date: 2014-02-14

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2015-08-04

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2015-10-13

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.


Patent
VentiRx Pharmaceuticals | Date: 2015-12-21

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.

Loading VentiRx Pharmaceuticals collaborators
Loading VentiRx Pharmaceuticals collaborators